Amoxicillin: A broad spectrum antibiotic

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 3, Issue 3, 2011, Pages 30-37

  Kaur, Simar Preet ^a   Rao, Rekha ^a   Nanda, Sanju ^b  

^a MAHARISHI MARKANDESHWAR DEEMED TO BE UNIVERSITY   (India)

^b MAHARSHI DAYANAND UNIVERSITY   (India)

Author keywords

Amoxicillin; Antibiotic; Review

Indexed keywords

AMOXICILLIN; AMPICILLIN; AZITHROMYCIN; AZLOCILLIN; CEFALORIDINE; CEFALOTIN; CEFAMANDOLE; CEFOXITIN; CEFUROXIME; CEPHAMYCIN; CHLORAMPHENICOL; CLARITHROMYCIN; CLAVULANIC ACID; COLISTIN; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; FLUCLOXACILLIN; KANAMYCIN; LANSOPRAZOLE; METICILLIN; METRONIDAZOLE; MEZLOCILLIN; PENICILLIN G; PENICILLIN V; STREPTOMYCIN; SULFONAMIDE; TETRACYCLINE DERIVATIVE; TICARCILLIN; UNINDEXED DRUG;

AGRANULOCYTOSIS; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ANTIBIOTIC THERAPY; ANUS PRURITUS; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL ENDOCARDITIS; BONE DISEASE; BONE MARROW APLASIA; CHOLESTASIS; CONVULSION; CRYSTALLURIA; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ERUPTION; DRUG EXCRETION; DRUG TOLERABILITY; DUODENUM ULCER; EAR INFECTION; ERYTHEMA; ERYTHEMA MULTIFORME; GASTROINTESTINAL SYMPTOM; GONORRHEA; HAIRY TONGUE; HELICOBACTER INFECTION; HEMODIALYSIS PATIENT; HEMOLYTIC ANEMIA; HEMORRHAGIC COLITIS; HEPATITIS; HUMAN; IMMUNOCOMPROMISED PATIENT; INTERSTITIAL NEPHRITIS; LEUKOPENIA; LIQUID CHROMATOGRAPHY; LOWER RESPIRATORY TRACT INFECTION; MORBIDITY; MORTALITY; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NOSE INFECTION; OTOTOXICITY; PHARYNGITIS; PHYSICAL CHEMISTRY; POTENTIOMETRIC TITRATION; REVIEW; SIDE EFFECT; SKIN INFECTION; SKIN MANIFESTATION; SOFT TISSUE INFECTION; STEVENS JOHNSON SYNDROME; STOMACH DISEASE; TOOTH DISCOLORATION; TOOTH DISEASE; TOXIC EPIDERMAL NECROLYSIS; ULTRAVIOLET SPECTROSCOPY; UROGENITAL TRACT INFECTION; URTICARIA; VASCULITIS; VOMITING;

EID: 79960753401     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Brogden RN, Heel RC, Speight TM, Avery GS. Amoxicillin injectable: a review of its antibacterial spectrum, pharmacokinetics and therapeutic use. Drugs 1979; 18(3): 169-184.
2. Bush K. β-lactam antibiotics: Penicillin, and other β-lactam antibiotics. In: Finch RG, Greenwood D, Norrby SR., and Whitley RJ. Antibiotic and chemotherapy: anti-infective agents and their use in therapy. 8th ed. Philadelphia (USA): Churchill Livingstone, an imprint of Elsevier Science Limited; 2003. p. 224-78.
3. El-Sooud KA, Al-Tarazi YH, Al-Bataineh MM. Comparative pharmacokinetics and bioavailability in chickens after intravenous, intramuscular and oral administration. Veter Res Comm 2004; 28(7): 599-607.
4. Gordon RC, Regamey C, Kirby WMM. Comparative clinical pharmacology of amoxicillin and ampicillin administered orally. Antimicrob Agents Chemotherapy 1972; 1(6): 504-507.
5. Nolan CM, Chalhub EG, Nash DG, Yamauchi T. Treatment of bacterial meningitis with intravenous amoxicillin. Antimicrob Agents Chemotherapy 1979; 16(2): 171-175.
6. Neu HC. Antimicrobial activity and human pharmacology of amoxicillin. J Infect Diseases 1974; 129 Suppl: 123-131.
7. United States Pharmacopoeia-30 and National Formulary-25: The Official Compendia of Standards. Rockvile (US): United States Pharmacopoeial Convention; 2007. p. 1402-1407.
8. British Pharmacopoeia.2009 ed. Vol I & II. London: British Pharmacopoeia Commission, 2009.p. 353-367.
9. Indian Pharmacopoeia. 5th ed. Vol 2. Ghaziabad (INDIA): Indian Pharmacopoeia Commission; 2007. p. 100-107.
10. Bodey GP, Nance J. Amoxicillin: in-vitro and pharmacological studies. Antimicrob Agents Chemotherapy 1972; 1(4): 358-362.
11. Saker L, Lee K, Cannito B, Gilmore A, Lendrum DC. Globalization and infectious diseases: a review of the linkage. UNICEF/UNDP/World Bank/WHO Special Programme for Research & Training in Tropical Diseases 2004. Special topic no. 3. TDR/STR/SEB/ST/04.2. 2004; Available from:
12. http://apps.who.int/tdr/publications/tdr-researchpublications/globalization-infectiousdiseases/pdf/seb_topic3.pdf
13. Durand S. Executive Summary - The globalization of infectious disease. Charles Westoff and Alan Rosenfield, reviewer. Population Resource Center Washington, D.C. (USA). February 2000; Available from:
14. http://www.prcdc.org/files/Infectious_Disease.pdf
15. WHO World Health Report 2005. Available from:
16. http://www.who.int/whr/2005/annexes-en.pdf
17. Geddes AM, Klugman AP, Rolinson GN. Introduction: historical perspective and development of amoxicillin/clavulanate. Inter J Antimicrob Agents 2007; 30Suppl: 109-112.
18. WHO World Health Report 2004. Available from: http://www.who.int/whr/2004/annex/en/index.htm
19. Subhas CM, Harsha R, Dinesha R, Thammanna GSS. Antibacterial activity of Coleus aromaticus leaves. Inter J of pharmacy and pharmaceutical sciences 2010; 2(3):63-66.
20. Harbarth S, Nobre V, Pittet D. Does antibiotic selection impact patient outcome. Healthcare Epidemiol Clin Infect Diseases 2007; 44: 87-93.
21. Garau J. Role of β-lactam agents in the treatment of communityacquired pneumonia. Eur J Clin Microbiol Infect Diseases 2005; 24: 83-99.
22. Reeves DS, Bullock DW. The amino penicillins: development and comparative properties. Infection 1979; 7 Suppl 5: 425-433.
23. White AR, Kaye C, Poupard J, Pypstra R, Woodnutt G, Wynne B. Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent. J Antimicrob Chemother 2004; 53 Suppl 1: 3-20.
24. Bellis M. History of antibiotics: antibiotic timeline. [Online]. 1997; available from:
25. http://inventors.about.com/od/pstartinventions/a/Penicillin_2.htm
26. Rolinson GN. Forty years of β-lactam research. J Antimicrob Chemotherapy 1998; 41: 589-603.
27. Rolinson GN, Geddes AM. The 50th anniversary of the discovery of 6-aminopenicillanic acid (6-APA). Inter J Antimicrob Agents 2007; 29: 3-8.
28. Sutherland R, Croydon EAP, Rolinson GN. Amoxicillin: a new semi-synthetic penicillin. British Med J 1972; 3: 13-16.
29. Brittain HG, Florey K, editors. Analytical profiles of drug substances and excipients. Vol 23. London (UK): Academic press limited; 1994.
30. Tsuji A, Nakashima EMI, Hamano S, Yamana T. Physicochemical properties of amphoteric & lactam antibiotics I: stability, solubility, and dissolution behavior of amino penicillins as a function of pH. J Pharm Sci 1978; 67(8): 1059-1066.
31. Prankerd RJ. Critical compilation of pKa values for pharmaceutical substances. In: Harry G. Brittain, editor. Profiles of drug substances, excipients and related methodology: critical. 1st ed. Vol 33. London (UK): Academicpress, an imprint of Elsevier; 2007.
32. Deppermann KM, Lode H, Hoffken G, Tschink G, Kalz C, Koeppe P. Influence of ranitidine, pirenzepine, and aluminum magnesium hydroxide on the bioavailability of various antibiotics, including amoxicillin, cephalexin, doxycycline, and amoxicillin-clavulanic acid. Antimicrob Agents Chemotherapy 1989; 33(11): 1901-1907.
33. Indian Pharmacopoeia.4th ed. The Controller of Publications, New Delhi (INDIA): The Controller of Publications; 1996.p. 48-52
34. Rojanarata T, Opanasopit P, Ngawhirunpat T, Saehuan C, Wiyakrutta S, Meevootisom V. A simple, sensitive and green bienzymatic UV-spectro-photometric assay of amoxicillin formulations. Enzy Microb Technol 2010; 46: 292-296.
35. Amin AS, El-Ansary AL, Issa YM. Colorimetric determination of amoxicillin in pure form and in pharmaceutical preparations. Talanta 1994; 41(5): 691-694.
36. Nagaralli BS, Seetharamappa J, Melwanki MB. Sensitive spectrophotometric methods for the determination of amoxicillin, ciprofloxacin and piroxicam in pure and pharmaceutical formulations. J Pharm Biomed Anal 2002; 29: 859-864.
37. Dousa M, Hosmanova R. Rapid determination of amoxicillin in premixes by HPLC. J Pharm Biomed Anal 2005; 37: 373-377.
38. Torres RF, Consentino MO, Lopez MAB, Mochon MC. Simultaneous determination of 11 antibiotics and their main metabolites from four different groups by reversed-phase highperformance liquid chromatography-diode array-fluorescence (HPLC-DAD-FLD) in human urine samples. Talanta 2010; 81: 871-880.
39. Imoisili MA, reviewer. Clinical review. NDA [Online] 2007 [2008 January 23]; [132 pages]. Available from:
40. http://www.fda.gov/downloads/Drugs/DevelopmentApproval Process/DevelopmentResources/ucm071718.pdf
41. Amoxycillin.Available from: http://www.neisslabs.com/doctors_pdf/amoxycillin.pdf
42. Penta J, Jannu KK, Musthyala R. Antimicrobial studies of selected antibiotics and their combination with enzymes. Inter J of pharmacy and pharmaceutical sciences 2010; 2(3):43-44.
43. Brunton LL, Parker KL, Blumenthal DK, Buxton ILO. Goodman & Gilman's manual of pharmacology and therapeutics. USA: The McGraw-Hill Companies; 2008. p. 728-750. DOI.10.1036/0071443436.
44. Neu HC. Penicillins - New insights into their mechanisms of activity and clinical use. Bull NY Acad Med. 1982; 58(8): 681-695.
45. Curtin-Wirt C, Casey JR, Murray PC, Cleary CT, Hoeger WJ, Marsocci SM, et al. Efficacy of penicillin vs. amoxicillin in children with group a beta-hemolytic streptococcal tonsillopharyngitis. Clinical Pediatrics (Phila) 2003; 42(3): 219-225.
46. Lennon DR, Farrell E, Martin DR, Stewart JM. Once-daily amoxicillin versus twice-daily Penicillin V in group a {beta}- hemolytic Streprococcus pharyngitis. Arch Dis Child 2008; 93(6): 474-478.
47. Jacobson GF, Autry AM, Kirby RS, Liverman EM, Motley RU. A randomized controlled trial comparing amoxicillin and azithromycin for the treatment of Chlamydia trachomatis in pregnancy. Am J Obstet Gynecol 2001; 184(7): 1352-1354.
48. Luft BJ, Dattwyler RJ, Johnson RC, Luger SW, Bosler EM, Rahn DW, et al. Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial. Ann Intern Med 1996; 124(9): 785-791.
49. Calhoun KH, Hokanson JA. Multi center comparison of clarithromycin and amoxicillin in the treatment of acute maxillary sinusitis. Arch Fam Med 1993; 2(8): 837-840.
50. Aurangzeb B, Hameed A. Comparative efficacy of amoxicillin, cefuroxime and clarithromycin in the treatment of community - acquired pneumonia in children. J Coll Physicians Surg Pak.2003; 13(12): 704-707.
51. Pukander JS, Jero JP, Kaprio EA, Sorri MJ. Clarithromycin vsamoxicillin suspensions in the treatment of paediatric patientswith acute otitis media. Pediatr Infect Dis J 1993; 12 (12, Suppl3): 118-121.
52. Eppes SC, Childs JA. Comparative study of cefuroxime axetilversus amoxicillin in children with early Lyme disease. Pediatrics 2002; 109(6): 1173-1177.
53. Shah SH, Shah IS, Turnbull G, Cunningham K. Cefuroxime axetilin the treatment of bronchitis: comparison with amoxicillin in amulticentre study in general practice patients. Br J Clin Pract 1994; 48(4): 185-189.
54. Brodie DP, Griggs JV, Cunningham K. Comparative study ofcefuroxime axetil suspension and amoxicillin syrup in thetreatment of acute otitis media in general practice. J Int MedRes 1990; 18(3): 235-239.
55. Dattwyler RJ, Volkman DJ, Conaty SM, Platkin SP, Luft BJ.Amoxicillin plus probenecid versus doxycycline for treatmentof erythema migrans borreliosis. Lancet 1990; 336 (8728):1404-1406.
56. Paavonen J, Roberts PL, Stevens CE, Wolner-Hanssen P, Brunham RC, Hillier S, et al. Randomized treatment of mucopurulent cervicitis with doxycycline or amoxicillin. Am J Obstet Gynecol 1989; 161(1): 128-135.
57. Omudhome Ogbru. In: Jay W. Marks, editor. Amoxycillin, amoxil, dispermox, trimox. [Online]. 2010 [cited 2010 Sep 22]; [4 screens]. Available from: http://www.medicinenet.com/amoxycillin/article.htm
58. Tong DC, Rothwell BR. Antibiotic prophylaxis in dentistry: a review and practice recommendations. J Am Dent Assoc 2000; 131: 366-374.
59. Mikota SK, Plumb DC. Amoxicillin: the elephant formulary. 2003-06. Available from http://www.elephantcare.org/Drugs/amoxicil.htm.
60. Kurtz GS, Ribeiro FM, Vicente FL, Struchiner CJ. Development and validation of limited-sampling strategies for predicting amoxicillin pharmacokinetic and pharmacodynamic parameters. Antimicrob Agents and Chemotherapy 2001; 45(11): 3029-3036.
61. GlaxoSmithKline. AMOXIL ® (Amoxycillin) Prescribing Information. North Carolina (US): Research Triangle Park. September 2009. Available from: http://us.gsk.com/products/assets/us_amoxil.pdf
62. Chulavatnatol S, Charles BG. Determination of dose-dependent absorption of amoxicillin from urinary excretion data in healthy subjects. Br J Clin Pharmac 1994; 38: 274-277.
63. Barr WH, Zola EM, Candler EL, Hwang SM, Tendolkar AV, Shamburek R, et al. Differential absorption of amoxicillin from the human small and large intestine. Clin Pharmacol Ther 1994; 56: 279-285.
64. Eliopoulos GM, Thauvin C, Gerson B, Moellering RC. In vitro activity and mechanism of action of A21978c1, A novel cyclic lipopeptide antibiotic. Antimicrob Agents Chemotherapy 1985; 27(3): 357-362.
65. Bergan T, Carlsen IB. Bacterial kill rates of amoxicillin and ampicillin at exponentially diminishing concentrations simulating in vivo conditions. Infection 1980; 8 Suppl 1: 103-108.
66. Salvo F, Polimeni G, Moretti U, Conforti A, Leone R, Leoni O, et al. Adverse drug reactions related to amoxicillin alone and in association with clavulanic acid: data from spontaneous reporting in Italy. J Antimicrob Chemotherapy 2007; 60: 121-126.
67. Novartis. CURAM (Amoxycillin/Clavulanic acid). Auckland (NZ): New Zealand Limited. 8 June 2009. Available from: http://www.medsafe.govt.nz/profs/datasheet/c/Curamtabsus p.pdf
68. Ronchera CL, Hernández T, Peris JE, Torres F, Granero L, Jiménez NV, et al. Pharmacokinetic interaction between highdose methotrexate and amoxicillin. Ther Drug Monit. 1993; 15(5): 375-379.